Skip to content
drillr.ai
Sign up

300765.SZ

石药创新

SZSE · Consumer Defensive · C 制造业 · CN

CNY 45.24
−7.67%
Ask drillr

  • Aug 27, 2026, 09:14 UTC

    Shijiazhuang Pharma Innovation's controlled subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its SYH2092 injection in China.

    Source:

  • Aug 21, 2026, 02:03 UTC

    As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.

    Source:

  • Aug 17, 2026, 14:09 UTC

    CSPC Pharmaceutical Group's subsidiary CSPC Innovation Pharmaceutical reported a net profit of 1.261 billion yuan for the first half of 2026, turning around from a loss of 2.75 million yuan a year earlier, with revenue up 208.7% year-on-year to 3.24 billion yuan.

    Source:

  • Aug 3, 2026, 08:02 UTC

    Jushi Biologics, a controlled subsidiary of CSPC Innovation, initiated the Ib/II phase clinical trial (SYS6090-008) of SYS6090 injection in combination therapy for advanced or metastatic colorectal cancer; the product is a Class 1 therapeutic biologic recombinant fully human anti-PD-1 fusion IL-15 protein.

    Source:

  • Jul 31, 2026, 08:16 UTC

    Shiyao Innovation announced that its controlling subsidiary Jushi Biologics initiated a Phase II clinical trial of SYS6041 in combination therapy for recurrent ovarian cancer, which was approved by the National Medical Products Administration in June 2026.

    Source:

  • Jul 27, 2026, 11:51 UTC

    MegaStone Biologics received a full upfront payment of $420 million from AstraZeneca on May 29, 2026, and recognized part of it as revenue.

    Source:

  • Jul 27, 2026, 09:24 UTC

    CSPC Innovation expects to turn a profit in the first half of 2026, achieving a high level of profitability.

    Source:

  • Jul 17, 2026, 08:17 UTC

    CSPC Innovation Pharmaceutical Group Co., Ltd. announced that its controlled subsidiary CSPC Megalith Biopharmaceutical Co., Ltd. received an Acceptance Notice from the National Medical Products Administration for the marketing application of Enweitrastuzumab injection.

    Source:

  • Jul 2, 2026, 08:55 UTC

    CSPC Innovation's controlled subsidiary Mega Stone Biologics has its injection SYS6043 included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration.

    Source:

  • Jun 25, 2026, 17:52 UTC

    CSPC Innovation Pharmaceutical Co. Ltd. is seeking a Hong Kong IPO to raise fresh capital.

    Source: